Overview
The World Health Organization defines infertility as failure to achieve pregnancy after 12 months or more of regular,
unprotected sexual intercourse. It can result from female factors, male factors, both, or remain unexplained after
evaluation. Infertility is not the same as recurrent pregnancy loss, although both deserve specialist care.
Ayurveda traditionally discusses reproductive health through Shukra Dhatu,
Artava, Apana Vata and the four
Garbha Sambhava Samagri: timing (Ritu), reproductive environment
(Kshetra), gametes (Beeja) and nourishment (Ambu). This is a cultural/traditional
framework, not a substitute for testing either partner.
Common causes
- Ovulation/endocrine: polycystic ovary syndrome, thyroid or pituitary disorders, reduced ovarian
reserve and age-related change.
- Pelvic/reproductive tract: blocked or damaged fallopian tubes, endometriosis, uterine cavity
abnormalities, fibroids in selected locations, infection or prior pelvic surgery.
- Sperm or ejaculation factors: low number, movement or function of sperm; obstruction, varicocele,
hormonal/genetic conditions, sexual dysfunction, medicines, testosterone/anabolic steroids or cancer treatment.
- Sometimes standard testing finds no single explanation. This does not mean the problem is imaginary or one
partner's fault.
Traditional assessment may describe altered Agni, Ama, dosha or tissue nourishment. These concepts
cannot diagnose blocked tubes, endometriosis, anovulation, diminished reserve or male-factor infertility, so medical
evaluation should occur in parallel.
Standard treatment and monitoring
Treatment is matched to age, cause, duration, test results, values and resources. No responsible treatment can guarantee
conception or a live birth.
- Options may include timed intercourse, treatment of an endocrine or sexual-health condition, ovulation induction,
selected surgery, intrauterine insemination (IUI), or in-vitro fertilization (IVF), sometimes with intracytoplasmic
sperm injection, donor gametes or gestational support.
- Fertility medicines require a clinician's protocol. Cycle tracking, blood tests and ultrasound may be used to assess
follicle growth, ovulation and treatment response and to reduce multiple-pregnancy and ovarian-hyperstimulation risks.
- Review the number of treatment cycles planned, age-specific success measures (pregnancy versus live birth), side
effects, multiple-pregnancy policy, embryo decisions and stop/review points before starting.
- Correct diagnosed deficiencies and optimize diabetes, thyroid disease, blood pressure and other chronic conditions.
Counselling or a fertility support service can help with grief, relationship strain and treatment fatigue.
Clinician-supervised Ayurvedic medicines and therapies
Integrative care can support wellbeing, but an Ayurvedic medicine has not been proven to unblock fallopian tubes, restore
depleted ovarian reserve, correct severe sperm abnormalities or guarantee pregnancy.
- A qualified Ayurvedic physician may consider an individualized routine, gentle yoga/breathing, external oil massage,
or a traditional rasayana/vajikarana formulation. The exact product, purpose and duration must be documented;
there is no safe public dose that applies to all people or fertility protocols.
- Products containing ashwagandha or shatavari are often promoted for fertility, but evidence for
conception and live birth is insufficient. Ashwagandha should be avoided during pregnancy and breastfeeding; it can
affect the thyroid or liver and interact with diabetes, blood-pressure, sedative, anticonvulsant, thyroid and
immune-suppressing medicines.
- Give both the fertility specialist and Ayurvedic clinician the full ingredient label before starting treatment.
Stop-at-positive-test rules must be agreed in advance; do not assume a product safe in early pregnancy because it is natural.
- Avoid unsupervised purgation, emesis, medicated enemas or intrauterine uttara basti. Dehydration, infection,
tissue injury or altered absorption may disrupt a fertility cycle. Invasive genital/uterine procedures belong only in
an appropriately regulated clinical setting with fertility-team agreement.
- Avoid unlabeled mixtures and herbo-mineral rasa/bhasma products unless a licensed clinician can verify
regulated manufacture and independent testing for lead, mercury, arsenic and other contaminants.
